INSERM ANRS VRI06

Version française

Design: Multicenter, randomized double-blind, phase 1
Status: Recruitment completed - Study in progress
Study duration per participant: 48 weeks

Study Title: « Phase I, multicenter, double-blind, placebo-controlled, dose-escalation trial of CD40-HIVRI.Env (anti-CD40 monoclonal antibody fused with Env GP140 clade C ZM-96 of HIV) adjuvanted vaccine, combined or not with the HIV-1 vaccine DNA-HIV-PT123 in healthy volunteers. »

VRI06 is a vaccine trial within the framework of a public academic research program against the AIDS virus.  It is organized and sponsored by Inserm-ANRS located in Paris. ANRS is an autonomous French public agency of Inserm (Institut national de la santé et de la recherche médicale) in charge of research on emerging infectious diseases, HIV/AIDS and viral hepatitis.

What is the purpose of this HIV vaccine trial?

The purpose of this HIV vaccine trial is to study the safety (absence of serious side effects) and immunogenicity (ability to induce immune responses) of a novel vaccine targeting dendritic cells (DC) for the development of a preventive vaccine against HIV/AIDS. The vaccine is administered alone or in combination with another HIV vaccine and at 3 different doses in order to determine the vaccine dose that induces the best stimulation of the immune system.